CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1 enrolled
Drug / intervention
Leflunomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04463615
NCT04463615Phase 2Completed
CompareCT.gov

Pilot Trial of Leflunomide in Patients With CD30+ Lymphoproliferative Disorders

City of Hope Medical Center·interventional·Posted Jul 9, 2020·Updated Dec 5, 2023

In Brief

A Phase 2 clinical trial evaluating Leflunomide for Recurrent Lymphoproliferative Disorder and Refractory Lymphoproliferative Disorder. Completed, enrolled 1 participant across 1 site.

Detailed Summary

This trial studies how well leflunomide works for the treatment of patients with CD30+ lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 9, 2020
Enrollment StartMay 5, 2021
Primary CompletionJul 28, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.0 years ago

Interventions

Leflunomidedrug

Given PO